Sandie Yu
About Sandie Yu
Sandie Yu serves as the Vice President of Global Market Access at Day One Biopharmaceuticals, where she oversees supply chain operations and patient support services. With extensive experience in market access and health economics, she has held key positions at several prominent pharmaceutical companies, including Medivation and Roche.
Work at Day One Biopharmaceuticals
Sandie Yu serves as the Vice President of Global Market Access at Day One Biopharmaceuticals. In this role, she leads operations for supply chain and patient support services. Her responsibilities include developing strategies for payer value and strategy, as well as managing payer accounts and overseeing health economics and outcomes research (HEOR). Sandie has been with Day One Biopharmaceuticals since 2021 and operates out of the San Francisco Bay Area.
Education and Expertise
Sandie Yu holds an undergraduate degree in Science/Biology from the University of California, Davis. She also earned an MBA from Cornell University - S.C. Johnson Graduate School of Management, completing her studies from 2000 to 2002. Her expertise includes developing strategies for global pricing, access policy, and reimbursement specifically for pediatric and orphan disease portfolios.
Background in Market Access and Policy
Prior to her current role, Sandie Yu held several positions in market access and policy. She was the Senior Director and Head of Market Access, Patient Advocacy, and Government Policy at Medivation from 2011 to 2017. She also worked as the Executive Director and Head of Market Access & Global Health Economics at LOXO Oncology, Inc. from 2017 to 2019. Her career includes extensive experience in payer strategy and health economics.
Previous Roles in the Pharmaceutical Industry
Sandie Yu has held various positions in the pharmaceutical industry. She worked at Roche Laboratories Inc as Product Director for Xeloda Breast Tumor Marketing from 2007 to 2009. Earlier in her career, she served as Product Manager for Invirase and Fuzeon Marketing at Roche Pharmaceuticals from 2003 to 2005, and as Market Analyst for Kytril, Tamiflu, and Fuzeon from 2002 to 2004. Additionally, she was the Marketing Director for Xeloda at Genentech from 2009 to 2011.